Inventor · disambiguated record
David Piwnica-Worms
Also filed as: PIWNICA-WORMS DAVID · PIWNICA-WORMS DAVID R
13 granted patents·10 pending applications·595 citations·filing 1990–2022
93Inventor score
Top patents by PatentIndex Score
23 records- 0197US6348185B1Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapyUNIV WASHINGTON·Filed 1999·Granted Feb 19, 2002·268 cites·21 claims
- 0294US6589503B1Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapyUNIV WASHINGTON·Filed 2000·Granted Jul 8, 2003·76 cites·42 claims
- 0392US7803351B2Blood brain barrier permeation peptidesUNIV WASHINGTON·Filed 2005·Granted Sep 28, 2010·10 cites·12 claims
- 0491US7306783B2Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapyUNIV WASHINGTON·Filed 2003·Granted Dec 11, 2007·41 cites·50 claims
- 0591US5403574AEvaluation and treatment of the multidrug resistance phenotypeBRIGHAM & WOMENS HOSPITAL·Filed 1992·Granted Apr 4, 1995·64 cites·8 claims
- 0689US7306784B2Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapyUNIV WASHINGTON·Filed 2003·Granted Dec 11, 2007·22 cites·43 claims
- 0776US9579408B2PET/SPECT agents for applications in biomedical imagingSHARMA VIJAY·Filed 2012·Granted Feb 28, 2017·2 cites·6 claims
- 0876US5186923AEnhancement of cellular accumulation of lipophilic cationic organometallic compounds by reduction of intramembrane potentialBRIGHAM & WOMENS HOSPITAL·Filed 1990·Granted Feb 16, 1993·43 cites·8 claims
- 0973US5277897AIn vivo enhancement of cellular accumulation of lipophilic cationic organometallic compounds by reduction of intramembrane potentialBRIGHAM & WOMENS HOSPITAL·Filed 1992·Granted Jan 11, 1994·37 cites·16 claims
- 1070US8652442B2Bioluminescence imaging of myeloperoxidase activity in vivo, methods, compositions and apparatuses thereforPIWNICA-WORMS DAVID·Filed 2009·Granted Feb 18, 2014·2 cites·6 claims
- 1167US7442518B2Imaging regulated protein-protein interactions in cells and living animals by enhanced luciferase protein fragment complementationUNIV WASHINGTON·Filed 2004·Granted Oct 28, 2008·3 cites·7 claims
- 1265US5407653AEvaluation of the multidrug resistance phenotypeBRIGHAM & WOMENS HOSPITAL·Filed 1991·Granted Apr 18, 1995·27 cites·19 claims
- 1356US2010121031A1Membrane-permeant peptide complexes for treatment of sepsisUNIV WASHINGTON·Filed 2009·Application pending·0 cites
- 1452US2009264355A1Methods to treat alzheimer's disease or other disorders mediated by amyloid-beta accumulation in a subjectUNIV ST LOUIS·Filed 2006·Application pending·0 cites
- 1552US2024279225A1Compounds and methods for theranostic targeting of parp activityUNIV TEXAS·Filed 2022·Application pending·0 cites
- 1646US2008233589A1Complementation Systems Utilizing Complexes of HeteroproteinsUNIV ST LOUIS·Filed 2006·Application pending·0 cites
- 1746US2023022045A1Combination therapies for the treatment of cancerUNIV TEXAS·Filed 2020·Application pending·0 cites
- 1845US2023014398A1Anti-b7-h3 monoclonal antibody and methods of use thereofUNIV TEXAS·Filed 2020·Application pending·0 cites
- 1945US2006263382A1Membrane-permeant peptide complexes for treatment of sepsisHOTCHKISS RICHARD·Filed 2006·Application pending·0 cites
- 2043US2022218851A1Compounds and methods for imaging immune activityUNIV TEXAS·Filed 2020·Application pending·0 cites
- 2140US8038984B2Membrane-permeant peptide complexes for treatment of sepsisUNIV WASHINGTON·Filed 2005·Granted Oct 18, 2011·0 cites·18 claims
- 2240US2009012025A1Methods and Compositions for Treatment of SepsisHOTCHKISS RICHARD·Filed 2008·Application pending·0 cites
- 2326US2015273088A1Zaprinast analogues as glutaminase inhibitors and methods to predict response theretoUNIV TEXAS·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when David Piwnica-Worms files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →